The FDA has granted Fast Track designation to pelareorep in combination with a checkpoint inhibitor for pretreated, advanced squamous cell carcinoma of the anal canal based on phase 1/2 GOBLET trial ...
Data presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting reflect a general trend toward moving targeted therapies into earlier-stage disease among patients with advanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results